cancers-logo

Journal Browser

Journal Browser

Post-Neoadjuvant Strategies in Breast Cancer (2nd Edition)

A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Therapy".

Deadline for manuscript submissions: 31 January 2026 | Viewed by 2674

Special Issue Editors


E-Mail Website
Guest Editor
Department of Radiation Oncology, Heinrich Heine University, 40225 Dusseldorf, Germany
Interests: cancer research; mediator response; chemotherapy; radiation therapy
Special Issues, Collections and Topics in MDPI journals

E-Mail Website
Guest Editor
Department of Obstetrics and Gynecology, Medical Faculty and University Hospital, Heinrich-Heine University Duesseldorf, Moorenstraße 5, 40225 Duesseldorf, Germany
Interests: minimal residual disease in breast and gynecologic cancers; CTC-based therapeutic strategies
Special Issues, Collections and Topics in MDPI journals

E-Mail Website
Guest Editor
Department of Radiation Oncology, LMU Munich, 81377 Munich, Germany
Interests: breast cancer; radiotherapy; deep inspiration breath hold
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

This Special Issue is the second edition of a previous issue on the topic of “Post-Neoadjuvant Strategies in Breast Cancer” (https://www.mdpi.com/journal/cancers/special_issues/Post_neoadjuvant_Cancers).

The post-neoadjuvant setting in early breast cancer is an attractive scenario for improving patient outcome by stratifying the adjuvant treatment according to the pathological response to the neoadjuvant systemic treatment. This strategy allows for studying new systemic therapies or new combinations of treatment modalities in high-risk patients who did not achieve pathologic complete response after primary treatment.

In this context, the findings after neoadjuvant therapy can be used as an in vivo sensitivity test, and further tailored treatment can improve the outcome in high-risk patients. Moreover, tailored de-escalation strategies of locoregional treatments could be another step towards reducing morbidity in patients with good response rates. To date, there is no clear evidence and there is no standard therapy routinely proposed for patients with residual disease after neoadjuvant chemotherapy, and few trials have addressed this setting. Therefore, the treatment of patients in the post-neoadjuvant setting remains a clinical challenge, with only a limited amount of data supporting the use of additional adjuvant chemotherapy.

The present Special Issue of Cancers focuses on recent advances and future perspectives in the various aspects of post-neoadjuvant strategies in breast cancer patients.

Prof. Dr. Edwin Bölke
Prof. Dr. Tanja Fehm
Dr. Stefanie Corradini
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • chemotherapy
  • prospective trials
  • clinical investigation
  • breast tumor
  • local recurrence
  • overall survival

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Review

17 pages, 467 KB  
Review
Optimizing Post-Neoadjuvant Treatment in Early Triple-Negative Breast Cancer
by Hervé Bischoff, Laura Somme and Thierry Petit
Cancers 2025, 17(20), 3288; https://doi.org/10.3390/cancers17203288 - 10 Oct 2025
Viewed by 2461
Abstract
Neoadjuvant therapy has become the standard of care in early-stage triple-negative breast cancer (TNBC), providing both prognostic information and a platform for treatment individualization. The achievement of a pathological complete response (pCR) is strongly associated with excellent long-term outcomes, whereas the presence of [...] Read more.
Neoadjuvant therapy has become the standard of care in early-stage triple-negative breast cancer (TNBC), providing both prognostic information and a platform for treatment individualization. The achievement of a pathological complete response (pCR) is strongly associated with excellent long-term outcomes, whereas the presence of residual disease (RD) indicates a markedly increased risk of recurrence. This dual prognostic value has established post-neoadjuvant treatment as a critical arena for risk-adapted strategies. In patients achieving pCR, de-escalation of adjuvant therapy is under active investigation, with several randomized trials assessing whether surveillance may safely replace prolonged immunotherapy. Conversely, the management of patients with RD has become increasingly complex, as clinicians must navigate between established options such as capecitabine, olaparib, and pembrolizumab, while antibody-drug conjugates are likely to emerge as future therapeutic options in this high-risk setting. In parallel, locoregional approaches are evolving, with trials evaluating axillary de-escalation and even the omission of surgery in highly selected cases. Looking forward, the integration of biomarkers such as circulating tumor DNA and tumor-infiltrating lymphocytes may help refine these strategies, paving the way toward truly personalized post-neoadjuvant care in TNBC. Full article
(This article belongs to the Special Issue Post-Neoadjuvant Strategies in Breast Cancer (2nd Edition))
Show Figures

Figure 1

Back to TopTop